BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• 

  Business

  Amgen Lays Off 350 Employees Following $27.8B Horizon Acquisition

  In its most recent round of layoffs this year, the California-based biopharma company is letting go of 350 former Horizon Therapeutics staff whose roles overlap with existing positions at Amgen.

  October 25, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Araclon’s Alzheimer’s Vaccine Shows Clean Safety Profile in Phase II Analysis

  While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.

  October 25, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Career Advice

  Candidates Expect More than the Job Market Can Deliver

  In a cooling job market, companies often can’t match job seekers’ expectations on factors such as salary and remote work.

  October 25, 2023

   · 

  5 min read

   · 

  Hayley Shasteen
• 

  FDA

  Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS

  The oncology company added a fifth indication for its isocitrate dehydrogenase 1 inhibitor, securing the greenlight for treating patients with IDH1-mutated relapsed or refractory myelodysplastic syndromes.

  October 25, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  GSK Looks to Push RSV Vaccine to Younger Seniors with New Phase III Data

  The company’s respiratory syncytial virus vaccine Arexvy can elicit similar levels of immune protection in adults aged 50 to 59 as in its approved population, finds results from a late-stage study.

  October 25, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Opinion: How AI Can Accelerate and Improve Clinical Trial Recruitment

  New platforms are emerging to help biopharma companies fill their human studies more efficiently, but barriers remain to their successful implementation.

  October 25, 2023

   · 

  3 min read

   · 

  Gaurav Gupta
• 

  BioForest

  How the Pandemic Shifted the Rules of Recruiting

  Traditional ideas of what attracts talent have, in many ways been upended, with some locations faring better than others. And what employees look for in a job is still changing.

  October 25, 2023

   · 

  4 min read

   · 

  Amanda Heidt
• 

  Drug Development

  Optimizing Biomarker Assays to Bridge the Clinical Trial Participation Gap

  High multiplexed patient-centric assays could reduce patient burden

  October 25, 2023

   · 

  3 min read

   · 

  BioSpace Insights
• 

  Drug Development

  Psychedelics Poised for the Therapeutic Mainstream

  With the potential FDA approval of an MDMA-based therapy for PTSD on the horizon, biopharma stakeholders are eyeing psychedelics with fresh anticipation.

  October 25, 2023

   · 

  5 min read

   · 

  Amanda Heidt
• 

  Drug Development

  Navigating the Challenges of Clinical Trial Design

  Protocol design optimization and timely engagement of regulators are the crux of optimized, patient-centric clinical trials.

  October 25, 2023

   · 

  6 min read

   · 

  BioSpace Insights